Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Day One Biopharmaceuticals (DAWN) Change in Accured Expenses (2022 - 2025)

Historic Change in Accured Expenses for Day One Biopharmaceuticals (DAWN) over the last 4 years, with Q3 2025 value amounting to $4.1 million.

  • Day One Biopharmaceuticals' Change in Accured Expenses rose 10786.19% to $4.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.0 million, marking a year-over-year decrease of 2421.26%. This contributed to the annual value of $42.1 million for FY2024, which is 29815.59% up from last year.
  • Per Day One Biopharmaceuticals' latest filing, its Change in Accured Expenses stood at $4.1 million for Q3 2025, which was up 10786.19% from $490000.0 recorded in Q2 2025.
  • Day One Biopharmaceuticals' 5-year Change in Accured Expenses high stood at $62.3 million for Q2 2024, and its period low was -$51.9 million during Q3 2024.
  • For the 4-year period, Day One Biopharmaceuticals' Change in Accured Expenses averaged around $2.6 million, with its median value being $1.8 million (2023).
  • Over the last 5 years, Day One Biopharmaceuticals' Change in Accured Expenses had its largest YoY gain of 344252.42% in 2024, and its largest YoY loss of 469955.67% in 2024.
  • Day One Biopharmaceuticals' Change in Accured Expenses (Quarter) stood at $2.1 million in 2022, then soared by 178.0% to $5.9 million in 2023, then skyrocketed by 468.93% to $33.4 million in 2024, then tumbled by 87.8% to $4.1 million in 2025.
  • Its Change in Accured Expenses stands at $4.1 million for Q3 2025, versus $490000.0 for Q2 2025 and -$27.0 million for Q1 2025.